Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer

Clinical Breast Cancer

Volumn 9, Issue 4, 2009, Pages 237-242

  Yardley, Denise A ^a,b   Burris III, Howard A ^a,b   Markus, Tiffanie ^a   Spigel, David R ^a,b   Greco, F Anthony ^b   Mainwaring, Mark ^b   Waterhouse, David M ^c   Webb, Charles D ^d   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Oncology Hematology Care Inc   (United States)

^d Consultants in Blood Disorders and Cancer ^*  (United States)

Author keywords

Dexamethasone; Gastrointestinal toxicity; Platelet derived growth factor receptor; Tumor interstitial fluid pressure

Indexed keywords

ANTIEMETIC AGENT; DOCETAXEL; IMATINIB; LOPERAMIDE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; LACRIMATION DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

EID: 73349116185     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.040     Document Type: Article

References (23)

1. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:422-428
2. Hudis C, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:58-65.
3. Jones SE, Erban J, Overymoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-5551
4. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III results. J Clin Oncol 2002; 20:2812-2823
5. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112:1455-1461
6. Ellis MJ. The insulin-like growth factor network and breast cancer. Bowcock A, ed. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. Totowa, NJ: Humana Press; 1999:121.
7. Bergstein I, Brown A. WNT genes and breast cancer. Bowcock A, ed. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. Totowa, NJ: Humana Press; 1999:181.
8. Bronzert DA, Pantazis P, Antoniades HN, et al. Synthesis and secretion of PDGF by human breast cancer cell lines. Proc Natl Acad Sci USA 1987; 84:5763.
9. Kern FG. The role of fibroblast growth factors in breast cancer pathogenesis and progression. Bowcock A, ed. Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics. Totowa, NJ: Humana Press; 1999:59.
10. Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-2934
11. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62:5476-5484
12. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652
13. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349
14. Buchdunger E, Cioffi CL, Law N, et al. ABL protein-kinase inhibitor STI171 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145
15. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002; 99:1928-1937 (Pubitemid 34525471)
16. Byrd DM, Demetri GD, Joensuu H, et al. Evaluation of imatinib mesylate in patients with large-volume gastrointestinal stromal tumors. J Clin Oncol 2007; 25:5585 (Abstract 1005A).
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
18. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-3505
19. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-1219
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481
21. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis. A Hoosier Oncology Group trial. Cancer 2008; 113:723-732
22. Spigel DR, Hainsworth JD, Simons L, et al. Irinotecan, carboplatin, and imatinib in untreated extensive stage small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol 2007; 2:854-861
23. Hainsworth JD, Spigel DR, Sosman JA, et al. Treatment of advanced renal cell carcinoma with a combination of bevacizumab, erlotinib, and imatinib: A phase I/II trial of the Minnie Pearl Cancer Research Network. Clin Genitourinary Cancer 2007; 5:427-432